What You Were Buying Last Week: GlaxoSmithKline plc

A strong pipeline, forecast growth and a massive dividend all may have attracted buyers to GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One of Warren Buffett’s famous investing sayings is “be fearful when others are greedy and greedy only when others are fearful“. Or, in other words, sell when others are buying and buy when they’re selling.

But we might expect Foolish investors to know that, and looking at what Fools have been buying recently might provide us with some ideas for good investments.

So, in this series of articles, we look at what customers of The Motley Fool ShareDealing Service were buying in the past week or so, and explore what might have made them decide to do so.

Heading in the right direction

gskSince a slight slump in the first week of August, the share price of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has risen 5.7% — not bad in just three weeks. 

Mind you, the pharma giant has still lost close to 10% in value so far this year. But perhaps the recent rise was enough to convince some people that Glaxo’s share price is now heading in the right direction again.

Whatever the case, enough people bought Glaxo last week to put the company in the number 1 spot in our latest “Top 10 Buys” list*.

Generating growth

Perhaps they were persuaded by Glaxo’s pipeline of potential products. After all, it was less than a year ago that analyst-house Morningstar rated GlaxoSmithKline’s product pipeline the best of 11 leading pharmaceutical companies. 

That pipeline has already started to deliver. Glaxo  recently launched new products in two main therapeutic areas: Breo and Anoro in respiratory and Tivicay HIV, saying that uptake of the latter has been “very strong“.

And there should be more to come before too long — in July Glaxo said that it had over 40 candidate products in late stage development. And what comes could well be very lucrative — Glaxo also said that 30 of its R&D assets have the potential to be “first class” in a range of therapeutic areas. 

Of course, not all of the candidate products will make it to market — even the most promising treatments can fail in trials at the last minute. But with such a large and diversified pipeline Glaxo should be well placed to generate growth.

Indeed, analyst forecasts suggest there’ll be around 11% earnings growth in 2015, resulting in earnings per share (EPS) of 106p.  That’d put Glaxo on a forward price-to-earnings ratio of 13.7, just above the current sector average of 13.3.

Main attraction

One of the main attractions of Glaxo has always been its dividend, and nothing’s changed there. If anything, it’s got more attractive of late — Glaxo’s current yield is a massive 5.7%, which is way ahead of the FTSE 100 average, plus there will be a substantial one-off return of cash next year, the proceeds of Glaxo’s recent deal with Novartis.

Maybe a 5.7% yield seems a bit too good? Perhaps it’ll have to fall. Given Glaxo’s commitment to year-on-year dividend growth, if the dividend has to fall, the share price should rise to even things out. If the yield were to drop even just to 5% next year, and Glaxo pays out the 84p estimated by analysts, that’d give a share price of 1,680p — a rise of 15% from today’s 1,460p.

But, of course, whatever other people were doing last week, only you can decide if Glaxo is a buy right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jon Wallis owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

* based on aggregate data from The Motley Fool ShareDealing Service.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »